Literature DB >> 21477895

[Candidemias: multicentre analysis in 16 hospitals in Andalusia (Spain)].

M Jesús Rodríguez-Hernández1, Maite Ruiz-Pérez de Pipaon, Manuel Márquez-Solero, Patricia Martín-Rico, Juan José Castón-Osorio, Francisca M Guerrero-Sánchez, Elisa Vidal-Verdú, Carolina García-Figueras, Alfonso Del Arco-Jiménez, Jesús Rodríguez-Baño, Estrella Martín-Mazuelos, José Miguel Cisneros-Herreros.   

Abstract

INTRODUCTION: Candidemia is a nosocomial infection with high associated mortality. There have been changes in microbiology, epidemiology and treatment over the last few years, which has led us to analyse our own situation.
MATERIAL AND METHODS: Prospective, multicentre and observational study. All episodes of candidemia in adult patients seen in 17 Andalusian hospitals from 1 October 2005 to 30 September 2006 were included.
RESULTS: Were detected 220 cases, the incidence was 0.58 cases/1,000 hospital discharges. Candida albicans was the most frecuent species (53% of cases). The majority of isolates (89%) was susceptibility to fluconazole. Sepsis was the most frequent clinical manifestation (65.7%). The treatment was inadequate in 38.7% of cases. Overall mortality was 40%. On univarite analysis death was found to be significantly associated with: aged > 60 years, unknown candidemia focus, Pitt score ≥ 2, APACHE II, shock at onset, persistents positive second blood cultures, non-removal of the central venous catheter and Candida species different of C. parasilopsis, among others. In the multivariate analysis death was found to be significantly associated with: aged > 60 years, Pitt score ≥ 2, Candida species different of C.parasilopsis and inadequate treatment.
CONCLUSIONS: The candidemia clinical epidemiology in our region is similar to other areas and receiving inadequate treatment is the only modifiable risk factor associated with higher odds of mortality. Therefore, this modifiable factor needs to be improved to reduce the mortality.
Copyright © 2010 Elsevier España, S.L. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21477895     DOI: 10.1016/j.eimc.2010.12.003

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN: 0213-005X            Impact factor:   1.731


  4 in total

1.  Whole-body physiology-based pharmacokinetics of caspofungin for general patients, intensive care unit patients and hepatic insufficiency patients.

Authors:  Qian-Ting Yang; Ya-Jing Zhai; Lu Chen; Tao Zhang; Yan Yan; Ti Meng; Lei-Chao Liu; Li-Mei Chen; Xue Wang; Ya-Lin Dong
Journal:  Acta Pharmacol Sin       Date:  2018-05-31       Impact factor: 6.150

2.  Recurrent episodes of candidemia due to Candida glabrata with a mutation in hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin.

Authors:  María Teresa Durán-Valle; Sara Gago; Alicia Gómez-López; Manuel Cuenca-Estrella; Leticia Jiménez Díez-Canseco; José Luis Gómez-Garcés; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2012-03-05       Impact factor: 5.191

3.  A prospective, multi-center study of Candida bloodstream infections in Chile.

Authors:  Maria E Santolaya; Luis Thompson; Dona Benadof; Cecilia Tapia; Paulette Legarraga; Claudia Cortés; Marcela Rabello; Romina Valenzuela; Pamela Rojas; Ricardo Rabagliati
Journal:  PLoS One       Date:  2019-03-08       Impact factor: 3.240

4.  Biomarkers of fungal infection: Expert opinion on the current situation.

Authors:  E Bouza; B Almirante; J García Rodríguez; J Garnacho-Montero; M Salavert; P Muñoz; M Sanguinetti
Journal:  Rev Esp Quimioter       Date:  2019-11-14       Impact factor: 1.553

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.